AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33835026 — intervention group
Group type: COMPARATOR
Intervention: Control arm (comparable group)
Number of subjects: 0
Study 33835026 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born into study sites after intervention
Number of subjects: 0
Study 32247714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent enteral feeding (six 4-hourly feeds per 24 h, n = 62)
Number of subjects: 121
Study 32247714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent enteral feeding
Number of subjects: 121
Study 32247714 — intervention group
Group type: COMPARATOR
Intervention: Continuous enteral feeding (n = 59)
Number of subjects: 121
Study 35428631 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery based on cerebral blood flow redistribution
Number of subjects: 0
Study 35428631 — intervention group
Group type: COMPARATOR
Intervention: Delayed delivery based on cCTG abnormalities or other worsening fetal condition
Number of subjects: 0
Study 34128862 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway (SGA) devices
Number of subjects: 66
Study 34128862 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) devices
Number of subjects: 66
Study 35191923 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy group (n=124): mechanical compression, intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment.
Number of subjects: 256
Study 35191923 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy group (n=124)
Number of subjects: 256
Study 35191923 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy group (n=132)
Number of subjects: 256
Study 34021031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist follow-up
Number of subjects: 71
Study 34021031 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 33453008 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbody forced air warming blanket
Number of subjects: 60
Study 33453008 — intervention group
Group type: COMPARATOR
Intervention: Over-body forced air warming blanket
Number of subjects: 60
Study 33155090 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Pivot (MP) TKA
Number of subjects: 53
Study 33155090 — intervention group
Group type: COMPARATOR
Intervention: Posterior Stabilized (PS) TKA
Number of subjects: 53
Study 35080078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon Essential Oil (LEO)
Number of subjects: 48
Study 35080078 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium Chloride (CPC)
Number of subjects: 48
Study 35080078 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 48
Study 35080078 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen Peroxide (H2O2)
Number of subjects: 48
Study 32338293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 136
Study 35312652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (single session and biweekly check-ins)
Number of subjects: 60
Study 35312652 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study 35151514 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Abstracts (VAs)
Number of subjects: 200
Study 35151514 — intervention group
Group type: COMPARATOR
Intervention: Key Figures (KFs)
Number of subjects: 200
Study 35760493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosgel (polymethylsiloxane polyhydrate)
Number of subjects: 440
Study 35760493 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label treatment with Enterosgel
Number of subjects: 440
Study 35760493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 34145803 — intervention group
Group type: COMPARATOR
Intervention: Nerve blockade (n=50)
Number of subjects: 161
Study 34145803 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) (n=52)
Number of subjects: 161
Study 34145803 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=59)
Number of subjects: 161
Study 34145803 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA (n=52)
Number of subjects: 161
Study 36562843 — intervention group
Group type: EXPERIMENTAL
Intervention: TII collagen
Number of subjects: 101
Study 36562843 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride + chondroitin sulfate (G + C)
Number of subjects: 101
Study 36562843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 33150187 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (M)
Number of subjects: 5
Study 33150187 — intervention group
Group type: COMPARATOR
Intervention: 24 h light (24HL)
Number of subjects: 5
Study 33150187 — intervention group
Group type: COMPARATOR
Intervention: 12 h light (12HL)
Number of subjects: 5
Study 33150187 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 5
Study 33150187 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 5
Study 33300323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry-guided remifentanil administration
Number of subjects: 54
Study 33300323 — intervention group
Group type: COMPARATOR
Intervention: Conventional remifentanil administration
Number of subjects: 54
Study 32992062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of the sciatic nerve and its branches using PHILIPSiU22 colour Doppler ultrasound with L12-5 high-frequency probe.
Number of subjects: 0
Study 35904728 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper survey
Number of subjects: 244
Study 35904728 — intervention group
Group type: COMPARATOR
Intervention: Telephone automated computer assisted structured interview (TACASI)
Number of subjects: 244
Study 33277980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant dimeglumine (FD) intravenously administered (test group)
Number of subjects: 29
Study 33277980 — intervention group
Group type: COMPARATOR
Intervention: Reference product (FD) intravenously administered (reference group)
Number of subjects: 29
Study 35438649 — intervention group
Group type: EXPERIMENTAL
Intervention: 686 Program plus Lay health supporters, e‐platform, award, and integration (LEAN)
Number of subjects: 277
Study 35438649 — intervention group
Group type: COMPARATOR
Intervention: 686 Program
Number of subjects: 277
Study 33769603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led personalized telephone lifestyle intervention
Number of subjects: 428
Study 33769603 — intervention group
Group type: COMPARATOR
Intervention: Automated SMSs
Number of subjects: 428
Study 34826572 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (n=108)
Number of subjects: 220
Study 34826572 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (n=112)
Number of subjects: 220
Study 33321447 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation
Number of subjects: 0
Study 35578409 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation of code white
Number of subjects: 24
Study 35578409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 35272485 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib + binimetinib + pembrolizumab
Number of subjects: 0
Study 35272485 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 0
Study 34060861 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective-taking condition (n = 45)
Number of subjects: 91
Study 34060861 — intervention group
Group type: COMPARATOR
Intervention: Objective condition (n = 46)
Number of subjects: 91
Study 33105016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab, a monoclonal antibody targeting IL-12/23
Number of subjects: 0
Study 33105016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0
Study 33105016 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 0
Study 35950949 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-monthly viral load (VL) testing with additional drug exposure and drug resistance testing in case of viral rebound.
Number of subjects: 501
Study 35950949 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care monitoring according to WHO-guidelines (annual VL testing).
Number of subjects: 501
Study 35950949 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-monthly VL testing.
Number of subjects: 501
Study 35950949 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care monitoring (annual VL testing).
Number of subjects: 501
Study 34794285 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) plus UDCA
Number of subjects: 102
Study 34794285 — intervention group
Group type: COMPARATOR
Intervention: UDCA
Number of subjects: 102
Study 32438493 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO-model incorporating fetal NT and eight ultrasonographic facial markers
Number of subjects: 624
Study 32438493 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO-model in retest set
Number of subjects: 624
Study 32438493 — intervention group
Group type: COMPARATOR
Intervention: LASSO-model compared to model based on fetal NT and maternal age
Number of subjects: 624
Study 32438493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram of LASSO-model
Number of subjects: 624
Study 33092424 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 172
Study 33092424 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 172
Study 33092424 — intervention group
Group type: EXPERIMENTAL
Intervention: R value, K value, α angle, and MA at 3 days after surgery
Number of subjects: 172
Study 35867153 — intervention group
Group type: EXPERIMENTAL
Intervention: NightLase
Number of subjects: 40
Study 35867153 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 40
Study 33541338 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program based on enhanced maternal care and positive multisensory stimulation
Number of subjects: 0
Study 33541338 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 32773816 — intervention group
Group type: EXPERIMENTAL
Intervention: FSD denture (CAD/CAM)
Number of subjects: 20
Study 32773816 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 20
Study 35943798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice a day
Number of subjects: 15
Study 35943798 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 15
Study 35943798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 15
Study 34115682 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 0.5%
Number of subjects: 85
Study 34115682 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 1.0%
Number of subjects: 85
Study 34115682 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 2.0%
Number of subjects: 85
Study 34115682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 35244287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rFSH (0.5 IU/kg/d)
Number of subjects: 30
Study 35244287 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose rFSH (1.1 IU/kg/d)
Number of subjects: 30
Study 35244287 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rFSH (2.2 IU/kg/d)
Number of subjects: 30
Study 35244287 — intervention group
Group type: COMPARATOR
Intervention: Control group (ovulatory controls)
Number of subjects: 30
Study 36507215 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole administration (group A)
Number of subjects: 43
Study 36507215 — intervention group
Group type: COMPARATOR
Intervention: No adjuvants (group B)
Number of subjects: 43
Study 33616598 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE)
Number of subjects: 0
Study 32961353 — intervention group
Group type: EXPERIMENTAL
Intervention: Body 50 (n=19)
Number of subjects: 93
Study 32961353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip 50 (n=29)
Number of subjects: 93
Study 32961353 — intervention group
Group type: EXPERIMENTAL
Intervention: Body 400 (n=24)
Number of subjects: 93
Study 32961353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tip 400 (n=21)
Number of subjects: 93
Study 32961353 — intervention group
Group type: COMPARATOR
Intervention: Control (n=16)
Number of subjects: 93
Study 35788868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed program with supplemental support (n=110)
Number of subjects: 220
Study 35788868 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control condition (n=110)
Number of subjects: 220
Study 33637048 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) treatment
Number of subjects: 0
Study 35943883 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 50 mg/d
Number of subjects: 0
Study 35943883 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 100 mg/d
Number of subjects: 0
Study 35943883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Riboflavin 50 and 100 mg/d
Number of subjects: 0
Study 35943883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33580297 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐d‐glucan‐enriched mixture (10.4 g/day) from Lentinula edodes
Number of subjects: 52
Study 33580297 — intervention group
Group type: COMPARATOR
Intervention: Placebo incorporated in three different commercial creams
Number of subjects: 52
Study 32819461 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800
Study 32819461 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study 35109864 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature (containing four PET/CT features and four clinical factors)
Number of subjects: 196
Study 35109864 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature for stage III patients (containing two clinical features and two radiomics features)
Number of subjects: 196
Study 35109864 — intervention group
Group type: EXPERIMENTAL
Intervention: K-M curves of both models
Number of subjects: 196
Study 35109864 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected radiomics features
Number of subjects: 196
Study 32920843 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 90
Study 32920843 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC)
Number of subjects: 90
Study 32555624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (2 sessions/week)
Number of subjects: 52
Study 32555624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (6 sessions/week)
Number of subjects: 52
Study 32555624 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 52
Study 35507468 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic suprapectoral biceps tenodesis (ASPBT)
Number of subjects: 73
Study 35507468 — intervention group
Group type: COMPARATOR
Intervention: Open subpectoral biceps tenodesis (OSPBT)
Number of subjects: 73
Study 34244154 — intervention group
Group type: COMPARATOR
Intervention: Phone counseling
Number of subjects: 0
Study 34244154 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0
Study 34244154 — intervention group
Group type: EXPERIMENTAL
Intervention: Web + Phone counseling
Number of subjects: 0
Study 32358874 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMEO ULE
Number of subjects: 45
Study 32358874 — intervention group
Group type: COMPARATOR
Intervention: Therapist‐assisted Table Top (TAT)
Number of subjects: 45
Study 32205274 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Energy Regulation Group (TG)
Number of subjects: 22
Study 35997978 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (15 mg daily)
Number of subjects: 984
Study 35997978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 33108910 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning + text message intervention (n=29)
Number of subjects: 60
Study 33108910 — intervention group
Group type: COMPARATOR
Intervention: Control (n=31)
Number of subjects: 60
Study 32341707 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 120
Study 32341707 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with chamomile-lavender essential oil
Number of subjects: 120
Study 32341707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both music therapy and aromatherapy with chamomile-lavender essential oil
Number of subjects: 120
Study 32341707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 35821512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT), 40 sessions daily
Number of subjects: 73
Study 33021146 — intervention group
Group type: EXPERIMENTAL
Intervention: Application to track daily walking steps and interact via text messages with group members for 4 weeks
Number of subjects: 60
Study 33021146 — intervention group
Group type: COMPARATOR
Intervention: Application only to track own walking steps
Number of subjects: 60
Study 32822286 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice daily)
Number of subjects: 303
Study 32822286 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (PCC)
Number of subjects: 303
Study 36384181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) in seven weekly sessions for eight weeks
Number of subjects: 36
Study 33693724 — intervention group
Group type: COMPARATOR
Intervention: Glycemic Load (GL) - highest quartile
Number of subjects: 66643
Study 33693724 — intervention group
Group type: COMPARATOR
Intervention: Glycemic Index (GI) - highest quartile
Number of subjects: 66643
Study 32854231 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment for 3 months
Number of subjects: 33
Study 32854231 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 33
Study 34064493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and antibiotherapy with surgical periodontal therapy
Number of subjects: 22
Study 34064493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen and antibiotherapy with surgical periodontal therapy
Number of subjects: 22
Study 34064493 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone alone
Number of subjects: 22
Study 34064493 — intervention group
Group type: COMPARATOR
Intervention: Routine scaling and polishing (Control group)
Number of subjects: 22
Study 33885041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic prophylaxis (low molecular weight heparin)
Number of subjects: 180932
Study 33885041 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic prophylaxis (unfractionated heparin)
Number of subjects: 180932
Study 33885041 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 180932
Study 34259402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with heat-sensitive moxibustion
Number of subjects: 60
Study 34259402 — intervention group
Group type: COMPARATOR
Intervention: Opioids according to the three-step analgesic method of WHO
Number of subjects: 60
Study 33169138 — intervention group
Group type: EXPERIMENTAL
Intervention: NORTH STAR
Number of subjects: 24
Study 33169138 — intervention group
Group type: COMPARATOR
Intervention: Assessment-and-feedback-only condition (Control)
Number of subjects: 24
Study 32299860 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 10355
Study 32299860 — intervention group
Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 10355
Study 32299860 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 10355
Study 33713397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides
Number of subjects: 0
Study 33713397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33103600 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided refutational messages
Number of subjects: 609
Study 33103600 — intervention group
Group type: COMPARATOR
Intervention: Conspiracy framed misinformation messages
Number of subjects: 609
Study 33103600 — intervention group
Group type: COMPARATOR
Intervention: Uncertainty framed misinformation messages
Number of subjects: 609
Study 36442435 — intervention group
Group type: COMPARATOR
Intervention: Basic health information presentation 1 (control group)
Number of subjects: 1066
Study 36442435 — intervention group
Group type: COMPARATOR
Intervention: Basic health information presentation 2 (control group)
Number of subjects: 1066
Study 34369941 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB plus buccal infiltration (1.8 mL IANB + 1.8 mL buccal infiltration)
Number of subjects: 60
Study 34369941 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB (3.6 mL)
Number of subjects: 60
Study 34369941 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB plus lingual infiltration (1.8 mL IANB + 1.8 mL lingual infiltration)
Number of subjects: 60
Study 34369941 — intervention group
Group type: COMPARATOR
Intervention: IANB
Number of subjects: 60
Study 34369941 — intervention group
Group type: COMPARATOR
Intervention: IANB plus lingual infiltration
Number of subjects: 60
Study 34369941 — intervention group
Group type: COMPARATOR
Intervention: IANB plus buccal infiltration
Number of subjects: 60
Study 33687747 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly guided therapy
Number of subjects: 628
Study 33687747 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 628
Study 32033532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strengthening and balance exercises
Number of subjects: 190
Study 32033532 — intervention group
Group type: COMPARATOR
Intervention: Stretching and relaxation exercises (Control)
Number of subjects: 190
Study 33065952 — intervention group
Group type: EXPERIMENTAL
Intervention: 40U daxibotulinumtoxinA
Number of subjects: 191
Study 33065952 — intervention group
Group type: COMPARATOR
Intervention: 20U onabotulinumtoxinA
Number of subjects: 191
Study 33065952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 33065952 — intervention group
Group type: COMPARATOR
Intervention: 20U daxibotulinumtoxinA
Number of subjects: 191